<amendment session="112" chamber="s" number="2130" updated="2022-02-25T17:31:35Z">
  <amends type="s" number="3187" sequence=""/>
  <status datetime="2012-05-24">withdrawn</status>
  <sponsor bioguide_id="B001135"/>
  <offered datetime="2012-05-22"/>
  <description>To ensure transparency in Food and Drug Administration user fee agreement negotiations.</description>
  <actions>
    <action datetime="2012-05-24">
      <text>Proposed amendment SA 2130 withdrawn in Senate.</text>
      <reference ref="CR S3563" label="consideration"/>
    </action>
    <action datetime="2012-05-24">
      <text>Considered by Senate.</text>
      <reference ref="CR S3536" label="consideration"/>
    </action>
    <action datetime="2012-05-23">
      <text>Amendment SA 2130 proposed by Senator Burr. (consideration: CR S3492-3495; text: CR S3492) To ensure transparency in Food and Drug Administration user fee agreement negotiations.</text>
    </action>
    <action datetime="2012-05-23">
      <text>Senate amendment proposed (on the floor): Amendment SA 2130 proposed by Senator Burr.</text>
      <reference ref="CR S3492-3495" label="consideration"/>
      <reference ref="CR S3492" label="text"/>
    </action>
    <action datetime="2012-05-22">
      <text>Senate amendment submitted</text>
    </action>
  </actions>
</amendment>
